WEDNESDAY, Jan. 25 (HealthDay News) -- Researchers who identified a protein that worsens symptoms of Parkinson's disease say their finding could eventually lead to new treatments for the neurodegenerative disease.
The protein, RGS4, normally helps regulate the activity in neurons in the striatum, the part of the brain that controls movement.
But in models of Parkinson's disease in mice, the researchers found that RGS4 actually contributes to problems with motor control, leading to a deterioration of movement and motor coordination.
The study, published online Jan. 25 in the journal Neuron, was conducted by scientists at the Gladstone Institutes, a nonprofit biomedical research organization affiliated with the University of California, San Francisco (UCSF).
It's long been known that decreased levels of the brain chemical dopamine are associated with Parkinson's. Patients take a drug called Levodopa to increase dopamine levels but the drug's effectiveness begins to weaken as the disease progresses.
This has led scientists to start looking for potential new treatment targets.
"About 60,000 Americans are diagnosed with Parkinson's annually, and dopamine-based therapies often do not provide a long-term solution," Anatol Kreitzer, a Gladstone investigator and an assistant professor of physiology and neurology at UCSF, said in a Gladstone news release.
"Our discovery that RGS4 may play a role in the development of Parkinson's symptoms helps us lay the groundwork for a new therapeutic strategy -- independent of dopamine," he claimed.
While studies involving animals can be promising, they frequently fail to produce similar results in humans.
The U.S. National Institute of Neurological Disorders and Stroke has more about Parkinson's disease.
SOURCE: Gladstone Institutes, news release, Jan. 25, 2012
Copyright © 2012 HealthDay. All rights reserved.
|Previous: Oldest Known Dinosaur Nesting Site Found||Next: Many Docs Use Costly MRIs to Diagnose Nerve Condition: Study|
Reader comments on this article are listed below. Review our comments policy.